Trending...
- Phinge CEO Ranked #1 Globally by Crunchbase for the Last Week, Will Be in Las Vegas Jan. 4-9, the Week of CES to Discuss Netverse & IPO Coming in 2026 - 103
- "Micro-Studio": Why San Diegans are Swapping Crowded Gyms for Private, One-on-One Training at Sweat Society
- Documentary "Prescription for Violence: Psychiatry's Deadly Side Effects" Premieres, Exposes Link Between Psychiatric Drugs and Acts of Mass Violence
DURHAM, N.C., May 27, 2022 /PRNewswire/ -- Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Pemetrexed Lyo. Injection to its line of chemotherapy drugs. The new drug is formulated as a sterile lyophilized (freeze-dried) powder to be reconstituted for intravenous infusion. Pemetrexed Lyo. Injection is therapeutically equivalent to Eli Lilly and Company's ALIMTA® and approved to treat Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Malignant Pleural Mesothelioma (MPM), a cancer of the inside lining of the chest cavity.1 Accord's product is offered in vials of 100mg, 500mg, and 1000mg strengths and is currently available to ship.
Pemetrexed Lyo. Injection is FDA-approved for use as a first-line treatment for locally advanced or metastatic NSCLC with non-squamous tissue type, a maintenance drug for metastatic NSCLC, a treatment for NSCLC that recurs after prior chemotherapy, and a treatment for MPM in patients whose cancer can't be removed surgically.2
"Accord Healthcare US has distinguished itself in oncology injectables, and the introduction of Pemetrexed Lyo. Injection to our portfolio strengthens our offering of oncology medications," said Accord CEO Jeff Hampton. "We are committed to making more generics available to patients. Our technical capabilities and manufacturing infrastructure have defined our company's history and the patients shape our future."
More on ncarol.com
Important Safety Information: Pemetrexed Lyo. Injection may cause fatigue or nausea and vomiting. Other possible side effects are serious, including fast heartbeat, chest pain, blistering and other skin reactions, and difficulty breathing. Pemetrexed is in a class of medications called antifolate antineoplastic agents and works by blocking the action of a certain substance in the body that may help cancer cells multiply.2
Further information about safety and potential side effects can be found in our product insert.
Pemetrexed was approved by the FDA for the treatment of Malignant Pleural Mesothelioma.3 For more information, please visit the Products page at Accord Healthcare US.
About Accord Healthcare US
Accord Healthcare, a wholly owned subsidiary of Intas Pharmaceuticals, is a leading generic pharmaceutical company. Accord is committed to improving lives by increasing access to medicines while also providing novel solutions that enhance the pharmaceutical experience for both healthcare providers and patients. Accord Healthcare combines its advanced manufacturing technology with in-house research to produce highly complex, affordable, and essential medicines. Accord Healthcare's forward-thinking, innovative approach, and its resolve to help patients remains at the heart of everything they do. Accord is headquartered in Durham, North Carolina. The Intas network markets its products in 80 countries. To learn more, visit the Accord website.
More on ncarol.com
References
1 Access data FDA.gov. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021462s021lbl.pdf. Accessed May 2022.
2 Pemetrexed Injection, National Library of Medicine, MedlinePlus. Available at: https://medlineplus.gov/druginfo/meds/a607043.html. Accessed May 2022.
3 FDA drug approval summaries: pemetrexed (Alimta), U.S. Food and Drug Administration. Available at: https://pubmed.ncbi.nlm.nih.gov/15477632/. Accessed May 2022.
Media Contact:
Kellyann Zuzulo
Em-Press Media
[email protected]
215.287.7291
SOURCE Accord Healthcare, Inc.
Pemetrexed Lyo. Injection is FDA-approved for use as a first-line treatment for locally advanced or metastatic NSCLC with non-squamous tissue type, a maintenance drug for metastatic NSCLC, a treatment for NSCLC that recurs after prior chemotherapy, and a treatment for MPM in patients whose cancer can't be removed surgically.2
"Accord Healthcare US has distinguished itself in oncology injectables, and the introduction of Pemetrexed Lyo. Injection to our portfolio strengthens our offering of oncology medications," said Accord CEO Jeff Hampton. "We are committed to making more generics available to patients. Our technical capabilities and manufacturing infrastructure have defined our company's history and the patients shape our future."
More on ncarol.com
- Guests Can Save 25 Percent Off Last Minute Bookings at KeysCaribbean's Village at Hawks Cay Villas
- Trump's Executive Order Rescheduling Cannabis: Accelerating M&A in a Multibillion-Dollar Industry
- Genuine Hospitality, LLC Selected to Operate Hilton Garden Inn Birmingham SE / Liberty Park
- tukr box Ministries Launches Meal-Sharing Kit Partnership With Marry Me Marinara
- Documentary "Prescription for Violence: Psychiatry's Deadly Side Effects" Premieres, Exposes Link Between Psychiatric Drugs and Acts of Mass Violence
Important Safety Information: Pemetrexed Lyo. Injection may cause fatigue or nausea and vomiting. Other possible side effects are serious, including fast heartbeat, chest pain, blistering and other skin reactions, and difficulty breathing. Pemetrexed is in a class of medications called antifolate antineoplastic agents and works by blocking the action of a certain substance in the body that may help cancer cells multiply.2
Further information about safety and potential side effects can be found in our product insert.
Pemetrexed was approved by the FDA for the treatment of Malignant Pleural Mesothelioma.3 For more information, please visit the Products page at Accord Healthcare US.
About Accord Healthcare US
Accord Healthcare, a wholly owned subsidiary of Intas Pharmaceuticals, is a leading generic pharmaceutical company. Accord is committed to improving lives by increasing access to medicines while also providing novel solutions that enhance the pharmaceutical experience for both healthcare providers and patients. Accord Healthcare combines its advanced manufacturing technology with in-house research to produce highly complex, affordable, and essential medicines. Accord Healthcare's forward-thinking, innovative approach, and its resolve to help patients remains at the heart of everything they do. Accord is headquartered in Durham, North Carolina. The Intas network markets its products in 80 countries. To learn more, visit the Accord website.
More on ncarol.com
- Price Improvement on Luxurious Lāna'i Townhome with Stunning Ocean Views
- Nextvisit Co-Founder Ryan Yannelli Identifies Six Critical Factors for Behavioral Health Providers Evaluating AI Scribes in 2026
- Elderhaus Receives 2025 Grant from The Endowment to Strengthen Services and Expand Community Impact
- CredHub and Real Property Management Join Forces to Empower Franchise Owners with Rental Payment Credit Reporting Solutions
- Leimert Park Announces Weeklong Kwanzaa Festival & Kwanzaa Parade Celebrating Black History, Culture, and Community
References
1 Access data FDA.gov. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021462s021lbl.pdf. Accessed May 2022.
2 Pemetrexed Injection, National Library of Medicine, MedlinePlus. Available at: https://medlineplus.gov/druginfo/meds/a607043.html. Accessed May 2022.
3 FDA drug approval summaries: pemetrexed (Alimta), U.S. Food and Drug Administration. Available at: https://pubmed.ncbi.nlm.nih.gov/15477632/. Accessed May 2022.
Media Contact:
Kellyann Zuzulo
Em-Press Media
[email protected]
215.287.7291
SOURCE Accord Healthcare, Inc.
Filed Under: Business
0 Comments
Latest on ncarol.com
- Microgaming Unveils Red Papaya: A New Studio Delivering Cutting-Edge, Feature-Rich Slots
- 5-Star Duncan Injury Group Expands Personal Injury Representation to Arizona
- NC State and Railinc Partner to Advance Freight Efficiency through Modal Rebalancing Study
- The End of "Influencer" Gambling: Bonusetu Analyzes Finland's Strict New Casino Marketing Laws
- AI-Driven Cybersecurity Leader Gains Industry Recognition, Secures $6M Institutional Investment, Builds Momentum Toward $16M Annual Run-Rate Revenue
- TRIO Heating, Air & Plumbing Now Ranks #1 in San Jose
- Milwaukee Job Corps Center Hosts Alumni Day, Calls Alumni to Action on Open Enrollment Campaign
- Golden Paper Identifies Global Growth in Packaging Papers and Upgrades Its High-End Production Capacity
- Champagne, Caviar Bumps & Pole Performances — Welcome the New Year Early with HandPicked Social Club
- A New Soul Album: Heart Of Kwanzaa, 7-Day Celebration
- Allegiant Management Group Named 2025 Market Leader in Orlando by PropertyManagement.com
- Local upholstery business expands services to meet growing demand in Shelby and Cleveland County
- NAFMNP Awarded USDA Cooperative Agreement to Continue MarketLink Program Under FFAB
- Costa Oil - 10 Minute Oil Change Surpasses 70 Locations with Construction of San Antonio, TX Stores — Eyes Growth Via Acquisition or Being Acquired
- LaTerra and Respark Under Contract with AIMCO to Acquire a $455M, 7-Property Chicago Multifamily Portfolio
- Record Revenue, Tax Tailwinds, and AI-Driven Scale: Why Off The Hook YS Inc. Is Emerging as a Standout in the $57 Billion U.S. Marine Market
- VSee Health (N A S D A Q: VSEE) Secures $6.0M At-Market Investment, Accelerates Expansion as Revenues Surge
- Children Rising Appoints Marshelle A. Wilburn as New Executive Director
- Fairmint CEO Joris Delanoue Elected General Director of the Canton Foundation
- Sleep Basil Mattress Co.'s Debuts New Home Page Showcasing Performance Sleep Solutions for Active Denver Lifestyles